| Recruiting | 3 | 1400 | Europe, Canada, Japan, US, RoW | Previously treated CAR-T patients | Novartis Pharmaceuticals, University of Pennsylvania | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | 02/36 | 02/36 | | |
NCT02862275: Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer |
|
|
| Active, not recruiting | 1 | 40 | Canada, US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI | National Cancer Institute (NCI) | Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | 11/25 | 11/25 | | |
